• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

FDA Panel Narrowly Rejects Xarelto for ACS

Article

An FDA advisory committee has voted 6-4, with one abstention, against expanding the marketing indications for the factor Xa inhibitor rivaroxaban (Xarelto) to include treatment of acute coronary syndrome (ACS).

The vote by the Cardiovascular and Renal Drugs Advisory Committee was somewhat surprising given the positive review from FDA staff released two days before the meeting, but it signals a growing reluctance to expand indications based on data from a single trial.

Read the full story: http://hcp.lv/Kdov5I

Source: MedPage Today

Related Videos
4 experts in this video
4 experts in this video
Rakendu Rajendran, MBBS
Vivek Bhalla, MD, Stanford University School of Medicine
Dr Carla Nester
Rayan Salih, MD, Northeast Georgia Health System
Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Mount Sinai Fuster Heart Hospital
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
Varsha Tanguturi, MD, MPH, Mass General Hospital
 Khush Kharidia, MD, UT Southwestern
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.